Brief: Algernon Pharmaceuticals Provides Update On Its Planned Phase II Clinical Trial
25/11/2019 12:25
Nov 25 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON ITS PLANNED
PHASE II
CLINICAL TRIAL
Source text for Eikon: ID:nGNX6Clwb2
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement